Over the past 10–15 years, the discovery of gene mutations in NSCLC such as EGFR, ALK, and other mutations with subsequent development of targeted therapies has dramatically changed the treatment landscape [57–60]. This evidence concerns the gene ALK and non-small cell lung carcinoma.